Literature DB >> 20651818

Involvement of sarcoplasmic reticulum in changing intracellular calcium due to Na+/K+-ATPase inhibition in cardiomyocytes.

Harjot K Saini-Chohan1, Ramesh K Goyal, Naranjan S Dhalla.   

Abstract

Earlier studies have demonstrated that ouabain-induced increase in [Ca2+]i, as a consequence of sarcolemma (SL) Na+/K+-ATPase inhibition, is associated with activation of both the SL Na+/Ca2+ exchanger and SL Ca2+ channels. In view of the importance of sarcoplasmic reticulum (SR) in the regulation of [Ca2+]i, this study examined the role of SR in ouabain-induced increase in [Ca2+]i in both quiescent and KCl-depolarized cardiomyocytes. For this purpose, adult rat cardiomyocytes were loaded with fura-2 and ouabain-induced changes in [Ca2+]i were monitored upon treatment with or without different agents that are known to influence Ca2+ handling by the intracellular organelles. Ouabain not only increased the basal [Ca2+]i and augmented KCl-induced increase in [Ca2+]i but also produced similar effects on the ATP-induced increase in [Ca2+]i. Treatments of cardiomyocytes with caffeine, ryanodine, or cyclopiazonic acid, which affect SR Ca2+ stores, attenuated the ouabain-induced increase in basal Ca2+ as well as augmentation of the KCl response. Both ryanodine and cyclopiazonic acid produced additional effects, when used in combination with a SL Ca2+ channel inhibitor (verapamil), but not with a Na+/Ca2+ exchange inhibitor (KB-R7943). Inhibitors of Ca2+/calmodulin kinase, protein kinase A, and inositol-3-phosphate receptors were also observed to depress the ouabain-induced increase in [Ca2+]i in cardiomyocytes. On the other hand, mitochondrial Ca2+ transport inhibitors did not exert any effect on the ouabain-induced alterations in [Ca2+]i in cardiomyocytes. Furthermore, ouabain did not show any direct effect on the Ca2+ uptake and Ca2+ release activities of SR or mitochondria. These results suggest an indirect involvement of SR Ca2+ stores in the ouabain-induced increase in [Ca2+]i in cardiomyocytes and indicate the participation of both Ca2+-induced Ca2+ release and regulatory mechanisms in this action.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20651818     DOI: 10.1139/y10-055

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  6 in total

1.  Ouabain increases iNOS-dependent nitric oxide generation which contributes to the hypertrophic effect of the glycoside: possible role of peroxynitrite formation.

Authors:  Xiaohong Tracey Gan; J Craig Hunter; Cathy Huang; Jenny Xue; Venkatesh Rajapurohitam; Sabzali Javadov; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2011-12-10       Impact factor: 3.396

2.  Differentially regulated functional gene clusters identified in early hypoxic cardiomyocytes.

Authors:  Do Kyun Kim; Eunmi Choi; Byeong-Wook Song; Min-Ji Cha; Onju Ham; Se-Yeon Lee; Chang Youn Lee; Jun-Hee Park; Heesang Song; Ki-Chul Hwang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

Review 3.  Drug-induced secretory diarrhea: A role for CFTR.

Authors:  Changsuk Moon; Weiqiang Zhang; Nambirajan Sundaram; Sunitha Yarlagadda; Vadde Sudhakar Reddy; Kavisha Arora; Michael A Helmrath; Anjaparavanda P Naren
Journal:  Pharmacol Res       Date:  2015-09-30       Impact factor: 7.658

4.  Regulation and rate limiting mechanisms of Ca2+ ATPase (SERCA2) expression in cardiac myocytes.

Authors:  Anand Mohan Prasad; Giuseppe Inesi
Journal:  Mol Cell Biochem       Date:  2011-10-01       Impact factor: 3.396

5.  Gestation changes sodium pump isoform expression, leading to changes in ouabain sensitivity, contractility, and intracellular calcium in rat uterus.

Authors:  Rachel V Floyd; Ali Mobasheri; Susan Wray
Journal:  Physiol Rep       Date:  2017-12

6.  Resolvin D1 mitigates energy metabolism disorder after ischemia-reperfusion of the rat lung.

Authors:  Qifeng Zhao; Ji Wu; Qingwang Hua; Zhiyong Lin; Leping Ye; Weixi Zhang; Guowei Wu; Jie Du; Jie Xia; Maoping Chu; Xingti Hu
Journal:  J Transl Med       Date:  2016-03-24       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.